Interventional radiology denied? We cite SIR, BCLC, and the trial data they ignored.

Why interventional radiology denials are different

Interventional radiology sits in a strange place on the insurer policy map. Many IR procedures — UFE for fibroids, PAE for BPH, Y-90 radioembolization for HCC, kyphoplasty for vertebral compression fracture, mechanical thrombectomy for pulmonary embolism — are minimally-invasive alternatives to bigger, more morbid surgical procedures. They are usually less expensive in total cost of care, but they have one structural disadvantage: insurer medical directors are often general internists, hospitalists, or surgeons who trained before these IR alternatives became standard of care. The result is a steady stream of denials that read like the policy was written in 2010, even when the procedure has been first-line since 2018.

The good news is that IR is one of the most evidence-rich subspecialties in medicine. The Society of Interventional Radiology (SIR), the BCLC algorithm for HCC, ACOG joint statements with SIR for UFE, and AASLD/EASL/Baveno VII guidance for portal-hypertension procedures all provide overturn-grade citations — when correctly invoked, they almost always meet or exceed the insurer's own coverage criteria. A successful IR appeal turns the policy back on the policy.

This guide walks through the most common IR denial categories, the citations that work, and the structure of an effective appeal letter.

The denial categories you will actually see

Across thousands of IR denials, six categories account for roughly 90% of all rejections:

1. "Try surgery first" — UFE denied in favor of hysterectomy or myomectomy; PAE denied in favor of TURP; ablation denied in favor of partial nephrectomy or hepatic resection; kyphoplasty denied because the fracture "will heal on its own."

2. "Investigational / experimental" — most often hits PAE (despite AUA/SIR support since 2020), GAE for knee OA, certain Y-90 protocols, and newer mechanical thrombectomy devices.

3. "BCLC stage / staging documentation insufficient" — for HCC procedures (TACE, Y-90), the insurer wants explicit BCLC staging, Child-Pugh score, MELD, and a multidisciplinary tumor-board recommendation.

4. "Conservative therapy not exhausted" — UFE denied without documented medical management trial; PAE denied without alpha-blocker / 5-ARI trial; kyphoplasty denied without 4-6 weeks of conservative therapy.

5. "Acuity / edema not documented" — kyphoplasty denied because the MRI does not show STIR/T2 edema confirming acute fracture.

6. "Tumor board not documented" — for any oncologic IR (Y-90, TACE, ablation), missing the multi-D note is fatal to the appeal.

Each one has a specific counter rooted in real evidence.

Uterine fibroid embolization: the FIBROID Registry and EMMY are your friends

UFE has been FDA-cleared and widely available since 1995, but it is still routinely denied — usually with the argument that "hysterectomy is the standard of care." That argument has been wrong for at least fifteen years.

The successful UFE appeal cites:

• The ACOG/SIR/ASRM Joint Statement (and ACOG Practice Bulletin No. 228, 2021 — Obstet Gynecol) — UFE is a recognized treatment option for symptomatic uterine leiomyomas in patients who decline or are not candidates for surgical management.
• The FIBROID Registry (Worthington-Kirsch Obstet Gynecol 2008) — multicenter prospective registry confirming high symptom-improvement rates and acceptable complication profile.
• The EMMY trial (Hehenkamp AJOG 2008; long-term Volkers AJOG 2007 / van der Kooij AJOG 2010) — RCT comparing UFE to hysterectomy with comparable symptom relief, faster recovery, and a substantial proportion avoiding hysterectomy at long-term follow-up.
• The REST trial (Edwards NEJM 2007; long-term Moss BJOG 2011) — RCT comparing UFE to surgery (hysterectomy or myomectomy).
• FEMME trial (Manyonda NEJM 2020) — UFE vs myomectomy in women wishing to retain uterus.

Documentation that anchors the appeal:

• MRI or ultrasound with dominant fibroid size in cm and total uterine volume in cc.
• Symptom log: PBAC (Pictorial Blood Loss Assessment Chart) for heavy menstrual bleeding, anemia (Hgb, ferritin), pelvic pressure, urinary frequency, dyspareunia.
• Medical-management trial: combined OCP, levonorgestrel IUD, tranexamic acid, GnRH analogue (leuprolide), or oral GnRH antagonist (elagolix or relugolix combination), with dates, dose, duration, and outcome.

Aetna CPB 0072 (Uterine Artery Embolization) and similar Cigna and UHC policies all require the medical-management log — but they cover UFE when the documentation matches the policy. The denial rationale "patient should have hysterectomy" is not a clinical argument; it is a financial one. Quote ACOG and SIR back at it.

Prostate artery embolization: the BPH alternative insurers haven't caught up to

PAE is the IR procedure most likely to be denied as "investigational" — and the most consistently overturnable on appeal. The evidence base is now robust:

• UK-ROPE Registry (Ray BJU Int 2018) — prospective multicenter UK registry; PAE achieves meaningful IPSS, QoL, and Qmax improvements.
• PARTEM trial (Abt BMJ 2018) — RCT comparing PAE to sham; positive primary endpoint.
• Carnevale et al Cardiovasc Intervent Radiol multiple RCTs comparing PAE to TURP in selected anatomies — non-inferior IPSS at 1 year with lower complication rate.
• AUA / SUFU Guideline on Surgical Management of Lower Urinary Tract Symptoms attributable to BPH (2023 amendment) — recognizes PAE as a treatment option in selected patients.
• SIR Position Statement on PAE (joint with AUA) — supports PAE in patients with prostate volume >=40 mL, IPSS >=12, Qmax <=12 mL/s after appropriate medical-therapy trial.

Documentation that anchors the appeal:

• IPSS (International Prostate Symptom Score) with subscales.
• Qmax on uroflow.
• Prostate volume on MRI or transrectal ultrasound.
• Medical-therapy trial: alpha-blocker (tamsulosin, alfuzosin, silodosin) plus 5-alpha-reductase inhibitor (finasteride or dutasteride) for >=6-12 months, with IPSS delta and tolerability documented.
• Surgical-alternative consideration: TURP / HoLEP / UroLift / Rezum considered, declined, or contraindicated (large prostate >80 mL, anticoagulation, frail).

When the insurer cites "investigational," attach the AUA 2023 amendment and the SIR Position Statement. Several large commercial plans updated their PAE policies in 2024 — but Medicare Advantage plans often lag. Cite current policy text, not the version on the website from two years ago.

TIPS: AASLD, EASL, and Baveno VII drive the appeal

Transjugular intrahepatic portosystemic shunt is well-established for refractory variceal bleeding and refractory ascites, but denials are common when the indication is borderline (early refractory ascites, recurrent rather than refractory bleeding) or the MELD is high.

The successful TIPS appeal cites:

• AASLD Portal Hypertensive Bleeding Guideline (Garcia-Tsao Hepatology 2017) — TIPS for recurrent variceal bleeding despite optimal endoscopic and medical management.
• AASLD ascites guidance — TIPS for refractory ascites with appropriate selection.
• Baveno VII (de Franchis J Hepatol 2022) — pre-emptive TIPS within 72 hours for high-risk variceal bleeding (Child-Pugh B with active bleeding or Child-Pugh C up to 13).
• EASL Clinical Practice Guidelines on Vascular Diseases of the Liver — TIPS for Budd-Chiari, portal vein thrombosis (selected), refractory ascites.

Documentation that anchors the appeal:

• MELD score (typically <18 for elective TIPS; higher for salvage situations with explicit risk-benefit framing).
• Child-Pugh class.
• Portal vein and hepatic vein patency on duplex / CT / MRI.
• Prior endoscopic banding sessions — number and outcomes.
• Beta-blocker therapy and tolerance, or contraindication.
• Paracentesis frequency for refractory ascites — typically >=3 large-volume paracenteses per month or intolerance.
• Pre-TIPS portal-systemic gradient measurement.
• Hepatic encephalopathy risk assessment — no severe baseline HE; lactulose / rifaximin plan for post-TIPS HE.

When the denial cites "high MELD," frame the request explicitly with risk-benefit including transplant candidacy.

Y-90 radioembolization and TACE for HCC: the BCLC algorithm is the appeal

For hepatocellular carcinoma, the Barcelona Clinic Liver Cancer (BCLC) algorithm (updated Reig J Hepatol 2022) is the framework all major insurers cite. Successful Y-90 and TACE appeals always document explicit BCLC staging:

• BCLC 0 (very early): single <2 cm, ECOG 0, Child-Pugh A — ablation or resection.
• BCLC A (early): single or up to 3 nodules <=3 cm, ECOG 0, Child-Pugh A-B — resection, ablation, or transplant. Y-90 segmentectomy increasingly used for BCLC A as bridge to transplant or definitive single-fraction therapy.
• BCLC B (intermediate): multifocal, ECOG 0, Child-Pugh A-B — TACE or Y-90.
• BCLC C (advanced): portal-vein invasion or extrahepatic spread — systemic therapy first-line; selected Y-90 for portal vein tumor thrombus.
• BCLC D (terminal): best supportive care.

Pivotal trial citations:

• LEGACY (Salem Hepatology 2021) — Y-90 segmentectomy with high response and survival rates in BCLC A.
• DOSISPHERE-01 (Garin Lancet Gastroenterol Hepatol 2021) — personalized dosimetry improves response and survival for locally advanced HCC.
• PRECISION V (Lammer Cardiovasc Intervent Radiol 2010) — DEB-TACE (drug-eluting beads) vs cTACE (conventional).
• SHARP (Llovet NEJM 2008) and REFLECT (Kudu Lancet 2018) — first-line systemic therapy for advanced HCC; cite for BCLC C framing when locoregional therapy is concurrent.
• REACH-2 (Zhu Lancet Oncol 2019) — second-line systemic therapy.
• AASLD Practice Guidance on HCC (Heimbach Hepatology 2018; updated Singal Hepatology 2023).

Documentation that anchors the appeal:

• BCLC stage explicit.
• Child-Pugh class.
• MELD score.
• ECOG performance status.
• Tumor-board note with date, attendees (HBP surgery, hepatology, medical oncology, radiation oncology, IR, pathology, radiology), and recommendation.
• MAA scan with lung shunt fraction (must be <20%, ideally <10%).
• Tumor-to-normal ratio for dosimetry.
• Planned dose with TheraSphere (glass) or SIR-Spheres (resin) selection rationale.
• Future liver remnant if combined with resection / transplant bridging.

When the denial says "stage wrong for Y-90," requote BCLC 2022 and the LEGACY/DOSISPHERE evidence.

Percutaneous tumor ablation: SIR Practice Parameter + lesion size

For renal cT1a tumors (<4 cm), liver oligometastases (selected), early-stage lung tumors (selected), and bone metastases, percutaneous ablation (cryo, RFA, microwave) is now widely accepted. The SIR Practice Parameter on Percutaneous Liver Tumor Ablation and the AUA/SUO Guideline on Renal Mass and Localized Renal Cancer (Campbell J Urol 2017 update) provide the framework.

Successful ablation appeals document:

• Lesion size and location with imaging measurements.
• RENAL nephrometry score for renal masses.
• Surgical alternative consideration — partial nephrectomy / hepatic resection considered, with explicit rationale for ablation (comorbid surgical risk, anatomic location favoring ablation, patient preference after informed consent, oligometastatic disease not surgically curable).
• Tumor board recommendation for oncologic cases.
• CHOSEN/COLDFIRE and SOLSTICE registry data for renal and liver ablation respectively.

For renal cryoablation specifically, the EORTC 30904 trial framework and long-term cohort data (Atwell J Urol 2013) support equivalent oncologic outcomes for cT1a tumors compared to partial nephrectomy in appropriately selected patients.

Vertebroplasty and kyphoplasty: VAPOUR and VERTOS IV defeat the "self-limiting" argument

Kyphoplasty and vertebroplasty denials almost always cite the older negative trials — Buchbinder NEJM 2009 and Kallmes NEJM 2009 (INVEST) — to argue that vertebral compression fractures are self-limiting and surgery is no better than sham. These trials enrolled patients with chronic, mixed-acuity, often edema-negative fractures, which is not the population for whom kyphoplasty is indicated.

The successful kyphoplasty/vertebroplasty appeal cites:

• VAPOUR (Clark Lancet 2016) — RCT of vertebroplasty vs sham in acute (<6 weeks), severe, edema-positive VCF; positive on pain and disability.
• VERTOS IV (Firanescu BMJ 2018) — RCT of vertebroplasty vs sham; positive in selected cohort.
• AANS / CNS / SIR / ASNR / ASSR Joint Practice Parameter on Vertebral Augmentation — supports vertebral augmentation in acute symptomatic VCF refractory to conservative therapy.
• NASS Coverage Policy — kyphoplasty / vertebroplasty.

Documentation that anchors the appeal:

• MRI with STIR/T2 edema confirming acute fracture (not chronic, healed, or edema-negative).
• Fracture age <6-12 weeks (varies by policy; some allow up to 12 weeks).
• Pain NRS >=5 despite >=4-6 weeks of conservative therapy (analgesics, brace, PT).
• No retropulsion / cord compression on imaging.
• Bone density with T-score documenting osteoporosis (when applicable).
• Distinction from older trials — explicitly note that VAPOUR / VERTOS IV inclusion criteria (acute, severe, edema-positive) match this patient.

When the insurer cites Buchbinder or Kallmes, distinguish the populations and pivot to VAPOUR / VERTOS IV.

PE intervention: PERT consensus and the new mechanical thrombectomy era

For massive and submassive pulmonary embolism, mechanical thrombectomy (FlowTriever / Inari) and catheter-directed thrombolysis (EkoSonic / ULTIMA-style protocols) have rapidly become standard for selected high-risk patients. Insurers are now catching up.

The successful PE intervention appeal cites:

• AHA Scientific Statement on Massive and Submassive PE (Jaff Circulation 2011) and updates.
• ESC 2019 PE Guideline (Konstantinides Eur Heart J 2020).
• PEITHO (Meyer NEJM 2014) — systemic thrombolysis benefit and bleeding risk in submassive PE.
• ULTIMA (Kucher Circulation 2014) — catheter-directed thrombolysis vs heparin.
• SEATTLE II (Piazza JACC Cardiovasc Interv 2015) — EkoSonic CDT.
• FLARE (Tu JACC Cardiovasc Interv 2019) — FlowTriever mechanical thrombectomy.
• FLASH Registry (Toma EuroIntervention 2022) — large prospective registry confirming FLARE findings.
• SIR Position on Acute PE Intervention and Multisociety Consensus on PE Response Teams (PERT).

Documentation that anchors the appeal:

• CTPA confirming central / lobar PE.
• RV/LV ratio >=0.9 (signal of right-heart strain).
• Troponin elevation and/or BNP elevation (myocardial injury / RV dysfunction).
• Hemodynamic status (tachycardia, hypotension, oxygen requirement).
• Bleeding-risk assessment if systemic thrombolysis was contraindicated.
• PERT consultation note if available.

Genicular artery embolization for knee osteoarthritis: stay on solid ground

GAE is the IR procedure most likely to be denied as "investigational" — and the evidence is genuinely still maturing. For appeals, lean on:

• GENESIS trial (Padia J Vasc Interv Radiol 2021) — single-arm prospective cohort.
• Bagla et al J Vasc Interv Radiol 2020 — early prospective data.
• SIR Position Statement on GAE — supports use in selected patients with mild-to-moderate knee OA refractory to conservative therapy who decline or are not candidates for arthroplasty.

Document conservative-therapy exhaustion (PT, NSAIDs, intra-articular steroid / hyaluronic acid, weight optimization) and the patient's decision-making rationale. Recognize that GAE will be one of the harder appeals; some plans are simply not yet covering it. Frame as bridge to arthroplasty or as alternative for arthroplasty-decliners with documented surgical risk.

The peer-to-peer call: ask for an IR-trained reviewer

Most IR denials carry a 14-day window for peer-to-peer review with the medical director. Demand it explicitly — and demand an IR-trained reviewer, not a general radiologist or internist. The IR community is small enough that most peer-to-peer reviewers will know the trial literature cold.

A successful IR peer-to-peer brings:

• Imaging measurements (lesion size, MELD, BCLC stage, RV/LV ratio, fibroid volume, prostate volume).
• The conservative / medical-therapy log.
• The specific guideline + pivotal trial citation matching the insurer's own policy.
• The tumor-board note, if oncologic.

Letter length, tone, escalation

A successful IR appeal is 1.5 to 2 pages, professional, firm, evidence-driven, and structured:

1. Header with member ID, claim number, procedure, CPT.

2. Diagnosis with ICD-10, lesion measurements, BCLC / Child-Pugh / MELD / RENAL / IPSS / fibroid volume as applicable.

3. Conservative or medical-therapy log with drugs, doses, durations, responses.

4. Address the denial reason directly — quote the insurer's own coverage criteria, demonstrate each is met, cite the controlling SIR / ACOG / AASLD / BCLC guideline plus the supporting trial.

5. For oncologic cases, attach the tumor-board note.

6. Closing — request overturn within deadline, demand IR-trained peer-to-peer.

When the first appeal fails, escalate per plan type. Self-funded ERISA plans go through second-level internal appeal then external review under ACA Section 2719. Fully-insured state-regulated plans go through state external review. Medicare Advantage cases route through the Independent Review Entity and the ALJ hearing. Medicaid follows the state Fair Hearing process. Each level has its own deadlines (typically 60-180 days from the prior denial).

What good looks like

A successful IR appeal letter:

• Quotes the insurer's own policy by name.
• Cites SIR by practice parameter or position statement; ACOG / AUA / AASLD / EASL / BCLC by guideline name; pivotal trials (FIBROID, EMMY, FEMME, UK-ROPE, PARTEM, LEGACY, DOSISPHERE, PRECISION-V, VAPOUR, VERTOS IV, FLARE, ULTIMA, SEATTLE II) by name and journal citation.
• Includes objective measurements (lesion size, BCLC stage, Child-Pugh, MELD, IPSS, Qmax, prostate volume, RENAL score, RV/LV ratio, lung shunt fraction, STIR edema for VCF) — not adjectives.
• Documents conservative/medical-therapy exhaustion or its medical contraindication.
• Attaches the multi-D tumor-board note for oncologic cases.
• Demands IR-trained peer-to-peer.
• Stays within 2 pages.

Most IR denials reverse on first appeal when SIR or BCLC is cited, the chart documentation matches the policy criteria, and the peer-to-peer is requested. The work is in the documentation — once the chart contains the right measurements and the right references, drafting the letter is mechanical.